Acamprosate Side Effects
Acamprosate is generally well-tolerated with diarrhea being the most common side effect, occurring in approximately 11% more patients than placebo, though it has no reported hepatotoxicity and does not require hepatic metabolism. 1
Common Side Effects
The most frequently reported adverse effects occurring at ≥3% and greater than placebo include 1:
Gastrointestinal:
- Diarrhea (most common, leading to discontinuation in 2% vs 0.7% placebo)
- Nausea
- Flatulence
- Anorexia
Neuropsychiatric:
- Anxiety
- Depression
- Dizziness
- Insomnia
- Paresthesia
- Dry mouth
Dermatologic:
- Pruritus
- Sweating
General:
- Asthenia (weakness)
- Accidental injury
- Pain
- Headache
Serious Adverse Effects
Suicidality and Depression
Acamprosate carries an FDA warning for increased suicidal events compared to placebo (1.4% vs 0.5% in studies ≤6 months; 2.4% vs 0.8% in year-long studies). 1 Completed suicides occurred in 0.13% of acamprosate patients versus 0.10% of placebo patients. While many events occurred during alcohol relapse, patients require monitoring for depression and suicidal ideation, with families/caregivers alerted to watch for these symptoms. 1
Rare Adverse Effects
- Extrapyramidal symptoms: One case report documented severe extrapyramidal symptoms in an elderly patient, potentially related to acamprosate's effects on dopamine via glutamatergic mechanisms 2
- Syncope: A case report suggests possible acamprosate-induced syncope in an elderly patient, though causality remains uncertain 3
- Acute kidney failure: Listed as a clinically significant serious adverse reaction 1
Discontinuation Rates
In placebo-controlled trials ≤6 months, 8% of acamprosate patients discontinued due to adverse events versus 6% on placebo. In longer studies, discontinuation rates were equal at 7% for both groups. 1 Only diarrhea accounted for >1% of discontinuations.
Safety in Special Populations
Hepatic Disease
A critical advantage of acamprosate is its lack of hepatic metabolism and absence of reported hepatotoxicity. 4 Multiple guidelines confirm that liver disease does not change acamprosate indications or dosing 5, making it particularly suitable for alcohol-associated liver disease patients. A phase 2 trial in patients with alcohol-associated liver disease (including those with MELD-Na ≥20) found no significant adverse events or worsening liver disease. 6
Renal Impairment
Acamprosate is contraindicated in severe renal impairment (CrCl ≤30 mL/min) and requires dose reduction in moderate impairment (CrCl 30-50 mL/min). 1 The drug undergoes renal excretion without metabolism. 4
Clinical Context
The overall adverse effect profile is mild and transient in most cases. 7, 8 Gastrointestinal effects, particularly diarrhea, typically occur early in treatment. 7 Importantly, acamprosate does not eliminate or diminish alcohol withdrawal symptoms 1, does not potentiate alcohol's toxic effects 8, and has no abuse potential. 8
The safety profile remains favorable compared to alternatives like naltrexone (which causes hepatotoxicity and is contraindicated in liver disease) and disulfiram (also hepatotoxic). 4, 9, 4 This makes acamprosate a preferred first-line option for patients with alcohol-associated liver disease requiring pharmacotherapy for relapse prevention.